Article Text
Miscellaneous
PF-3512676 may enhance the clinical activity of taxane/platinum chemotherapy in advanced non-small cell lung cancer
Statistics from Altmetric.com
Current first-line therapy for stage IIIB–IV non-small-cell lung cancer (NSCLC) is taxane plus platinum-based chemotherapy. With this regime the 1-year survival rate is less than 40%. Toll-like receptors (TLR) can stimulate innate and antigen-specific acquired immunity. PF-3512676 is a TLR9-activating oligodeoxynucleotide and has confirmed antitumour activity against a variety of cancers.
This randomised phase II study examined the …